Deferasirox is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta- thalassemia and other chronic anemias.

Deferasirox is marketed as Exjade, Desirox, Defrijet, Desifer, and Jadenu.

The half-life of deferasirox is between 8 and 16 hours allowing once a day dosing. Two molecules of deferasirox are capable of binding to 1 atom of iron which is subsequently eliminated by fecal excretion. Its low molecular weight and high lipophilicity allows the drug to be taken orally unlike deferoxamine which has to be administered by IV route (intravenous infusion). Together with deferiprone, deferasirox seems to be capable of removing iron from cells (cardiac myocytes and hepatocytes) as well as removing iron from the blood.

The major global manufacturers of Dillaros are Novartis, Cipla, Natco Pharma and Sun Pharma, among which Novartis is the industry leader with a market share of around 99%. North America is the largest spending region, with 30 per cent of the market, followed by Europe with 25 per cent.


Market Analysis and Insights: Global Deferasirox Market

In 2020, the global Deferasirox market size was US$ 2612.3 million and it is expected to reach US$ 3554.9 million by the end of 2027, with a CAGR of 4.5% during 2021-2027.

Global Deferasirox Scope and Market Size

Deferasirox market is segmented by region, by country, company, type, application and by sales channels. Players, stakeholders, and other participants in the global Deferasirox market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region, by country, company, type, application and by sales channels for the period 2016-2027.

Segment by Type, the Deferasirox market is segmented into

  • 500 mg/Tablet
  • 250 mg/Tablet
  • 125 mg/Tablet
  • Others

Segment by Application, the Deferasirox market is segmented into

  • Transfusional Iron Overload
  • NTDT Caused Iron Overload

Regional and Country-level Analysis:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • South Korea
  • India
  • Southeast Asia
  • Australia
  • Rest of Asia-Pacific
  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Russia
  • Nordic Countries
  • Rest of Europe
  • Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
  • Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Competitive Landscape and Deferasirox Market Share Analysis

Deferasirox market competitive landscape provides details and data information by companies. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2016-2021. It also offers detailed analysis supported by reliable statistics on sale and revenue by players for the period 2016-2021. Details included are company description, major business, Deferasirox product introduction, recent developments, Deferasirox sales by region, type, application and by sales channel.

The major companies include:

  • Novartis
  • Cipla
  • Natco Pharma
  • Sun Pharma

Table of content

1 Study Coverage
1.1 Deferasirox Product Introduction
1.2 Market by Type
1.2.1 Global Deferasirox Market Size Growth Rate by Type
1.2.2 500 mg/Tablet
1.2.3 250 mg/Tablet
1.2.4 125 mg/Tablet
1.2.5 Others
1.3 Market by Application
1.3.1 Global Deferasirox Market Size Growth Rate by Application
1.3.2 Transfusional Iron Overload
1.3.3 NTDT Caused Iron Overload
1.4 Study Objectives
1.5 Years Considered

2 Executive Summary
2.1 Global Deferasirox Market Size Estimates and Forecasts
2.1.1 Global Deferasirox Revenue 2016-2027
2.1.2 Global Deferasirox Sales 2016-2027
2.2 Deferasirox Market Size by Region: 2021 Versus 2027
2.3 Deferasirox Sales by Region (2016-2027)
2.3.1 Global Deferasirox Sales by Region: 2016-2021
2.3.2 Global Deferasirox Sales Forecast by Region (2022-2027)
2.3.3 Global Deferasirox Sales Market Share by Region (2016-2027)
2.4 Deferasirox Market Estimates and Projections by Region (2022-2027)
2.4.1 Global Deferasirox Revenue by Region: 2016-2021
2.4.2 Global Deferasirox Revenue Forecast by Region (2022-2027)
2.4.3 Global Deferasirox Revenue Market Share by Region (2016-2027)

3 Global Deferasirox by Manufacturers
3.1 Global Top Deferasirox Manufacturers by Sales
3.1.1 Global Deferasirox Sales by Manufacturer (2016-2021)
3.1.2 Global Deferasirox Sales Mar

276 5th Avenue, New York , NY 10001,United States
International: (+1) 646 781 7170 / +91 8087042414
Follow Us On linkedin :-